Smith+Nephew, the global medical technology company, has launched a five-year research partnership with Imperial College London aimed at accelerating innovation in robotic surgery.
The centre embeds Smith+Nephew engineers directly alongside Imperial researchers, departing from the traditional model of companies licensing technology from universities after the fact.
It marks the first time Smith+Nephew has founded a centre inside a university, and Imperial's first industry centre in medical technology.
The venture sits within Imperial's Hamlyn Centre, part of its Institute of Global Health Innovation, and will be led by Professor Ferdinando Rodriguez y Baena, whose group specialises in orthopaedic surgical robotics.
At full scale, it will support a senior postdoctoral researcher and up to seven fully funded PhD studentships recruited over the five years.
Research will target markerless registration and tracking, removing the pins and rigid markers current systems bolt to bone, and computer vision that reads and adapts to a patient's anatomy in real time.
The goal is robotic surgery that is less invasive and usable beyond specialist centres.
"This centre establishes a third route to patients: academic engineers working hand-in-hand to help develop products with a major industry partner," said Professor Rodriguez y Baena.
Vasant Padmanabhan, Smith+Nephew's President of Research & Development for ENT and Emerging Markets, said the centre has "the potential to move research into operating theatres at pace."
News Intelligence what this means for the company
Smith+Nephew has established a five-year embedded research partnership with Imperial College London to develop next-generation robotic surgery techniques for musculoskeletal conditions, marking the company's first university-based research centre and Imperial's first in medical technology. The model departs from traditional licensing by placing Smith+Nephew engineers directly alongside academic researchers, targeting innovations in markerless bone tracking and real-time computer vision to enable less invasive procedures deployable beyond specialist centres. This complements Smith+Nephew's existing rollout of its next-generation CORI XT handheld platform, extending the company's surgical robotics development pipeline into fundamental research.
The partnership signals Smith+Nephew's commitment to long-term innovation in surgical robotics but carries no immediate revenue impact; the five-year horizon and focus on early-stage research (markerless tracking, computer vision) suggest technologies are years from commercialisation. The move does not alter near-term product momentum but reinforces the company's positioning in the robotics-enabled orthopaedics market as a structural growth driver.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
